Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.25
+4.3%		$7.68
$1.95
▼
$12.43
$7.59B0.0323.76 million shs11.47 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$55.92
+2.2%		$53.56
$29.08
▼
$65.00
$8.07B1.231.43 million shs886,273 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$110.71
+4.7%		$101.58
$74.50
▼
$122.20
$7.59B1.92795,646 shs1.09 million shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$46.43
+16.3%		$35.73
$15.86
▼
$47.84
$2.26B1.57795,845 shs2.48 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-2.80%-0.29%-26.38%-17.06%+188.38%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+2.17%+0.16%-6.34%-4.22%+62.19%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+2.92%-2.09%-7.35%+9.49%+17.22%
Urogen Pharma stock logo
URGN
Urogen Pharma
+3.45%-2.35%+5.00%+52.08%+100.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.25
+4.3%		$7.68
$1.95
▼
$12.43
$7.59B0.0323.76 million shs11.47 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$55.92
+2.2%		$53.56
$29.08
▼
$65.00
$8.07B1.231.43 million shs886,273 shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$110.71
+4.7%		$101.58
$74.50
▼
$122.20
$7.59B1.92795,646 shs1.09 million shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$46.43
+16.3%		$35.73
$15.86
▼
$47.84
$2.26B1.57795,845 shs2.48 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-2.80%-0.29%-26.38%-17.06%+188.38%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+2.17%+0.16%-6.34%-4.22%+62.19%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
+2.92%-2.09%-7.35%+9.49%+17.22%
Urogen Pharma stock logo
URGN
Urogen Pharma
+3.45%-2.35%+5.00%+52.08%+100.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$14.2095.86% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.44
Hold$86.0053.79% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
2.78
Moderate Buy$142.3828.60% Upside
Urogen Pharma stock logo
URGN
Urogen Pharma
2.82
Moderate Buy$43.67-5.95% Downside

Current Analyst Ratings Breakdown

Latest URGN, PCVX, RYTM, and IBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/5/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$50.00 ➝ $60.00
8/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$154.00
8/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
8/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
National Bank Financial logo
National Bank Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$160.00
8/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$142.00 ➝ $143.00
8/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$141.00 ➝ $155.00
8/5/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Outperform$155.00 ➝ $160.00
7/27/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$145.00
7/21/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$32.00 ➝ $42.00
7/17/2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Urogen Pharma stock logo
URGN
Urogen Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M67.03N/AN/A($0.51) per share-14.22
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$20.51 per shareN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$189.76M39.98N/AN/A$2.08 per share53.23
Urogen Pharma stock logo
URGN
Urogen Pharma
$140.49M16.10N/AN/A($2.25) per share-20.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.85N/AN/AN/A-606.15%N/A-59.53%N/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%8/5/2026 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
-$153.49M-$2.75N/A28.66N/A-94.83%N/A-62.85%8/5/2026 (Estimated)

Latest URGN, PCVX, RYTM, and IBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$2.06-$1.97+$0.09-$1.97$12.50 millionN/A
8/5/2026Q2 2026
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.2650-$0.28-$0.0150-$0.28$63.55 million$72.46 million
8/4/2026Q2 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.22-$0.14-$0.22$49.80 million$51.24 million
8/4/2026Q2 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.8072-$0.73+$0.0772-$0.73$67.66 million$71.26 million
5/7/2026Q1 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.62-$0.54-$0.62$43.07 million$44.21 million
5/7/2026Q1 2026
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 million
5/6/2026Q1 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A
5/5/2026Q1 2026
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
6.67
6.66
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
7.49
7.49
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
4.17
3.89
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
4.69
4.28

Institutional Ownership

CompanyInstitutional Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%

Insider Ownership

CompanyInsider Ownership
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
66.10%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.30%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
5.90%
Urogen Pharma stock logo
URGN
Urogen Pharma
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
5901.05 billion355.05 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160144.40 million139.63 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14068.53 million64.49 millionOptionable
Urogen Pharma stock logo
URGN
Urogen Pharma
20048.72 million46.38 millionOptionable

Recent News About These Companies

Urogen Pharma Q2 Earnings Call Highlights
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-q2-earnings-call-highlights-2026-08-05/
UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript
August 5 at 3:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4931074-urogen-pharma-ltd-urgn-q2-2026-earnings-call-transcript
Urogen Pharma (NASDAQ:URGN) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS
August 5 at 2:55 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-nasdaqurgn-announces-quarterly-earnings-results-misses-estimates-by-002-eps-2026-08-05/
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
August 5 at 1:25 PM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/urogen-reports-50-4-million-of-zusduri-revenue-and-provides-second-quarter-2026-financial-results-and-highlights-1036412806
Urogen Pharma (NASDAQ:URGN) Stock Price Up 9.1% - Here's Why
August 5 at 12:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-nasdaqurgn-stock-price-up-91-heres-why-2026-08-05/
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
August 5 at 10:57 AM  |  zacks.comhttps://www.zacks.com/stock/news/2968630/urogen-pharma-urgn-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2968630
Swiss National Bank Makes New $1.40 Million Investment in Urogen Pharma $URGN
August 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-swiss-national-bank-makes-new-140-million-investment-in-urogen-pharma-urgn-2026-08-01/
UroGen Pharma (NASDAQ:URGN) Approaches A Defining Results Update
July 31, 2026  |  kalkinemedia.comK
Urogen Pharma (URGN) to Announce Quarterly Earnings on Thursday
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-urgn-to-announce-quarterly-earnings-on-thursday-2026-07-30/
Healthcare of Ontario Pension Plan Trust Fund Sells 738,026 Shares of Urogen Pharma $URGN
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-healthcare-of-ontario-pension-plan-trust-fund-sells-738026-shares-of-urogen-pharma-urgn-2026-07-30/
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
July 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/urogen-pharma-to-report-second-quarter-2026-financial-results-on-wednesday-august-5th-2026-1036377901
Ally Bridge Group NY LLC Purchases Shares of 202,124 Urogen Pharma $URGN
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ally-bridge-group-ny-llc-purchases-shares-of-202124-urogen-pharma-urgn-2026-07-29/
ADAR1 Capital Management LLC Boosts Stock Position in Urogen Pharma $URGN
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-adar1-capital-management-llc-boosts-stock-position-in-urogen-pharma-urgn-2026-07-29/
Urogen Pharma (NASDAQ:URGN) Receives Average Recommendation of "Moderate Buy" from Brokerages
July 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30927505
Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from Analysts
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-nasdaqurgn-receives-average-rating-of-moderate-buy-from-analysts-2026-07-29/
Elmind Capital LP Has $3.96 Million Position in Urogen Pharma $URGN
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-elmind-capital-lp-has-396-million-position-in-urogen-pharma-urgn-2026-07-28/
Urogen Pharma (NASDAQ:URGN) Reaches New 12-Month High - Here's What Happened
July 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/urogen-pharma-nasdaqurgn-reaches-new-12-month-high-heres-what-happened-2026-07-21/
UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat
July 20, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4923526-urogen-pharma-reimbursement-is-turning-zusduri-into-a-workflow-moat
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Urogen Pharma (URGN) and vTv Therapeutics (VTVT)
July 17, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/URGN-Q/pressreleases/3333206/analysts-offer-insights-on-healthcare-companies-rani-therapeutics-holdings-rani-urogen-pharma-urgn-and-vtv-therapeutics-vtvt/
Short sellers are betting against UroGen Pharma stock, but Wall Street expects 263% earnings growth in 2027
July 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/short-sellers-are-betting-against-urogen-pharma-stock-but-wall-street-expects-263-earnings-growth-in-2027/ar-AA288Kly
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ...
July 15, 2026  |  caledonianrecord.comC

New MarketBeat Followers Over Time

Media Sentiment Over Time

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$7.25 +0.30 (+4.32%)
Closing price 04:00 PM Eastern
Extended Trading
$7.32 +0.07 (+0.90%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$55.92 +1.23 (+2.25%)
Closing price 04:00 PM Eastern
Extended Trading
$58.16 +2.24 (+4.00%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$110.71 +4.93 (+4.66%)
Closing price 04:00 PM Eastern
Extended Trading
$112.86 +2.15 (+1.94%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$46.43 +6.51 (+16.31%)
Closing price 04:00 PM Eastern
Extended Trading
$45.95 -0.48 (-1.03%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas